148 related articles for article (PubMed ID: 38752448)
1. Toripalimab plus chemotherapy in American patients with recurrent or metastatic nasopharyngeal carcinoma: A cost-effectiveness analysis.
Lian D; Gan Y; Xiao D; Xuan D; Chen Y; Yang Y
Cancer Med; 2024 May; 13(10):e7243. PubMed ID: 38752448
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibition in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A CAPTAIN-1st and JUPITER-02 trial-based cost-effectiveness analysis.
Tian K; Han J; Wang Z; Chen J
Oral Oncol; 2022 May; 128():105842. PubMed ID: 35428025
[TBL] [Abstract][Full Text] [Related]
3. Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial.
Mai HQ; Chen QY; Chen D; Hu C; Yang K; Wen J; Li J; Shi Y; Jin F; Xu R; Pan J; Qu S; Li P; Hu C; Liu YC; Jiang Y; He X; Wang HM; Lim WT; Liao W; He X; Chen X; Wang S; Yuan X; Li Q; Lin X; Jing S; Chen Y; Lu Y; Hsieh CY; Yang MH; Yen CJ; Samol J; Luo X; Wang X; Tang X; Feng H; Yao S; Keegan P; Xu RH
JAMA; 2023 Nov; 330(20):1961-1970. PubMed ID: 38015220
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin in the first-line setting for Chinese patients with metastatic nasopharyngeal carcinoma.
Jin C; Zheng H; Zhan M; Wen F; Xu T
Eur Arch Otorhinolaryngol; 2020 Feb; 277(2):577-584. PubMed ID: 31720816
[TBL] [Abstract][Full Text] [Related]
5. Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma.
MacDonald K; Pondel M; Abraham I
J Med Econ; 2024; 27(sup3):1-8. PubMed ID: 38488887
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of tislelizumab in combination with chemotherapy for the first-line treatment of patients with metastatic or recurrent nasopharyngeal carcinoma in China.
Tang YK; Xu Z; Ye ZM; Li SR; Zhou Q
Head Neck; 2024 Jan; 46(1):5-14. PubMed ID: 37846175
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma.
Wu Q; Liao W; Huang J; Zhang P; Zhang N; Li Q
Oral Oncol; 2020 Apr; 103():104588. PubMed ID: 32070923
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
Chen X; Liang W; Wan N; Zhang L; Yang Y; Jiang J; Zhang T
Oral Oncol; 2019 Jul; 94():80-85. PubMed ID: 31178217
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China.
Zhao Z; Chen T; Zhou Z; Guo R; Liu Q
BMJ Open; 2023 Dec; 13(12):e071832. PubMed ID: 38110377
[TBL] [Abstract][Full Text] [Related]
10. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.
Mai HQ; Chen QY; Chen D; Hu C; Yang K; Wen J; Li J; Shi YR; Jin F; Xu R; Pan J; Qu S; Li P; Hu C; Liu YC; Jiang Y; He X; Wang HM; Lim WT; Liao W; He X; Chen X; Liu Z; Yuan X; Li Q; Lin X; Jing S; Chen Y; Lu Y; Hsieh CY; Yang MH; Yen CJ; Samol J; Feng H; Yao S; Keegan P; Xu RH
Nat Med; 2021 Sep; 27(9):1536-1543. PubMed ID: 34341578
[TBL] [Abstract][Full Text] [Related]
11. Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model.
Rui M; Shi F; Shang Y; Meng R; Li H
Adv Ther; 2020 Sep; 37(9):3761-3774. PubMed ID: 32647912
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of toripalimab combined with chemotherapy in the treatment of non-small cell lung cancer.
Wang H; Long Y; Xu Y; Liao L; Zhou Y
Front Public Health; 2023; 11():1137255. PubMed ID: 37033059
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
Patterson K; Prabhu V; Xu R; Li H; Meng Y; Zarabi N; Zhong Y; Batteson R; Pellissier J; Keefe S; Grivas P; de Wit R
Eur Urol Oncol; 2019 Sep; 2(5):565-571. PubMed ID: 31412011
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of toripalimab plus chemotherapy for advanced esophageal squamous cell carcinoma.
Xu K; Wu H; Zhou C; Bao Y; Yu M; Zhang L; Li X
Int J Clin Pharm; 2023 Jun; 45(3):641-649. PubMed ID: 36800145
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China.
Zhang M; Xu K; Lin Y; Zhou C; Bao Y; Zhang L; Li X
Front Immunol; 2023; 14():1169752. PubMed ID: 37313403
[TBL] [Abstract][Full Text] [Related]
16. First-line immunotherapy combinations for recurrent or metastatic nasopharyngeal carcinoma: An updated network meta-analysis and cost-effectiveness analysis.
Han J; Zeng N; Tian K; Liu Z; She L; Wang Z; He J; Chen N
Head Neck; 2023 Sep; 45(9):2246-2258. PubMed ID: 37435624
[TBL] [Abstract][Full Text] [Related]
17. Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis.
Kang S; Yin J
Expert Rev Pharmacoecon Outcomes Res; 2024 Jun; 24(5):653-659. PubMed ID: 38506058
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of toripalimab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma in China.
Kang S; Wang X; Pan Z; Liu H
Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):285-292. PubMed ID: 37855081
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness Analysis of Toripalimab Plus Paclitaxel and Cisplatin as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma.
Fang R; Wang S; Liu Y; Xu J
Adv Ther; 2023 Mar; 40(3):1019-1030. PubMed ID: 36622553
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.
Shi Y; Chen J; Shi B; Liu A
Gynecol Oncol; 2022 Feb; 164(2):379-385. PubMed ID: 34920886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]